Trial reportJournal of cachexia, sarcopenia and muscle2025
Evaluation of Weight Gain and Overall Survival of Men Versus Women With Advanced Non-Small Cell Lung Cancer.
Trial report in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
International, Randomized, Open-Label, Phase 3 Trial of Paclitaxel/Carboplatin Plus PF-3512676 Versus Paclitaxel/Carboplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer
International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer
Randomized, Open Label, Phase III Trial Of CP- 751,871 In Combination With Paclitaxel And Carboplatin Versus Paclitaxel And Carboplatin In Patients With Non Small Cell Lung Cancer
Who cites it
1 citing paper in PubMed.
- Evaluation of Weight Gain and Overall Survival of Men Versus Women With Advanced Non-Small Cell Lung Cancer.Journal of cachexia, sarcopenia and muscle · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWeight stabilization or gain during cancer treatment is associated with increased survival. Analyses of weight gain by sex during cancer treatment and the effects of weight on survival have not been fully studied. This post hoc analysis retrospectively examined the relationship between sex, weight gain and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) receiving standard-of-care chemotherapy.
methodsData from the control arms of three randomized phase III clinical studies (NCT00596830, NCT00254891, NCT00254904) of adult patients with advanced NSCLC were pooled; patients received platinum-based doublet chemotherapy. Weight was recorded according to each study's schedule. Analyses compared weight gain categories from baseline up to 3 months after chemotherapy initiation (> 0% vs. ≤ 0%, > 2.5% vs. ≤ 2.5% and > 5% vs. ≤ 5%). Stepwise Cox proportional hazards modelling of OS (time from treatment initiation to death due to any cause) was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs); differences between groups were tested with log-rank tests.
resultsOf the 1030 patients, most were men (70.5%) with stage IV NSCLC. Median (range) age was 62 (34-87) years for men and 60 (34-83) years for women, and the mean body mass index (standard deviation) was 24.5 (4.2) and 24.8 kg/m
conclusionsAny weight gain during treatment of advanced NSCLC was associated with a significantly reduced risk of death, regardless of sex.
trial registrationNCT00596830; NCT00254891; NCT00254904.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.